Comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) has been linked with histology and clinical outcomes to investigate heterogeneity in the genomic landscape of metastatic prostate cancer. Of the genomic alterations examined, which included alterations in AR, RB1 and TP53, only RB1 alteration was significantly associated with poor survival. Alterations in RB1, AR and TP53 were associated with shorter time on androgen receptor signalling inhibitor treatment. The study identifies molecularly defined groups of patients who might benefit from an aggressive treatment approach. The authors have made the tumour-level and patient-level data available for further research.
References
Original article
Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1902651116 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fenner, A. Genomic correlates of clinical outcomes. Nat Rev Urol 16, 448 (2019). https://doi.org/10.1038/s41585-019-0201-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0201-7